Ken Herrmann
University of Duisburg-Essen
CancerInternal medicineRadiologyPET-CTPathologyMagnetic resonance imagingOncologyProspective cohort studyMedical physicsPositron emission tomographyChemotherapyLymphomaProstate cancerNuclear medicineRadionuclide therapyIn patientCancer researchRadiation therapyClinical trialHistopathologyMedicine
Publications 532
#1Britta Heinze (University of Würzburg)H-Index: 6
#2Andreas Schirbel (University of Würzburg)H-Index: 27
Last. Martin Fassnacht (University of Würzburg)H-Index: 79
view all 0 authors...
Adrenal tumors represent a diagnostic and therapeutic challenge. Promising results have been obtained through targeting the cytochrome P450 enzymes CYP11B1 and CYP11B2 for molecular imaging, and [123/131I]iodometomidate ([123/131I]IMTO) has even been successfully introduced as a theranostic agent. As this radiopharmaceutical shows rapid metabolic inactivation, we aimed at developing new improved tracers. Several IMTO derivatives were newly designed by replacing the unstable methyl ester by diffe...
#1Nathalie Heynickx (UGent: Ghent University)
#2Ken Herrmann (UCLA: University of California, Los Angeles)H-Index: 67
Last. An AertsH-Index: 13
view all 5 authors...
Abstract At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. Howe...
#1Francesco Giammarile (IAEA: International Atomic Energy Agency)H-Index: 23
#2Roberto C. Delgado Bolton (UR: University of La Rioja)H-Index: 8
Last. Enrique Estrada L (IAEA: International Atomic Energy Agency)
view all 0 authors...
As a follow-up to the international survey conducted by the International Atomic Energy Agency (IAEA) in April 2020, this survey aims to provide a situational snapshot of the COVID-19 impact on nuclear medicine services worldwide, 1 year later. The survey was designed to determine the impact of the pandemic at two specific time points: June and October 2020, and compare them to the previously collected data. A web-based questionnaire, in the same format as the April 2020 survey was disseminated ...
Background: This study investigated the performance of simultaneous 18F-FDG PET/MRI of the breast as a platform for comprehensive radiomics analysis for breast cancer subtype analysis, hormone receptor status, proliferation rate and lymphonodular and distant metastatic spread. Methods: One hundred and twenty-four patients underwent simultaneous 18F-FDG PET/MRI. Breast tumors were segmented and radiomic features were extracted utilizing CERR software following the IBSI guidelines. LASSO regressio...
#1Robert SeifertH-Index: 10
Last. Thomas DeckerH-Index: 72
view all 0 authors...
INTRODUCTION Addition of cyclin-dependent 4/6 kinase (CDK4/6) inhibitors to endocrine therapy is standard of care in the treatment of women with advanced hormone receptor-positive HER2-negative breast cancer. However, the predictive factors for the treatment response to CDK4/6 inhibitor therapy are poorly elucidated. Early changes in the by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) uptake of tumors receiving different kinds of therapy have proven to reliably predict treatme...
#3Benedikt M. Schaarschmidt (University of Duisburg-Essen)H-Index: 9
Background: To evaluate the potential of simultaneously acquired 18F-FDG PET- and MR-derived quantitative imaging data sets of primary soft-tissue sarcomas for the prediction of neoadjuvant treatment response, the metastatic status and tumor grade. Methods: A total of 52 patients with a high-risk soft-tissue sarcoma underwent a 18F-FDG PET/MR examination within one week before the start of neoadjuvant treatment. For each patient, the maximum tumor size, metabolic activity (SUVs), and diffusion-r...
#1Andrei Gafita (UCLA: University of California, Los Angeles)H-Index: 4
#2Hui Wang (TUM: Technische Universität München)H-Index: 2
Last. Matthias Eiber (TUM: Technische Universität München)H-Index: 55
view all 22 authors...
Background: We aimed to systematically determine the impact of tumor burden on the 68Ga-prostate-specific membrane antigen-11 (68Ga-PSMA) PET biodistribution by the use of quantitative measurements. Methods: This international multicenter retrospective analysis included 406 men with prostate cancer who received 68Ga-PSMA PET/CT. Of these, 356 had positive findings and were stratified by quintiles into very low (Q1, ≤25 ml), low (Q2, 25-189 ml), moderate (Q3, 189-532 ml), high (Q4, 532-1355 ml) a...
#1Ken HerrmannH-Index: 67
#2Clemens Kratochwil (DKFZ: German Cancer Research Center)H-Index: 54
Last. Roland HustinxH-Index: 53
view all 5 authors...
#1Maja Guberina (University of Duisburg-Essen)H-Index: 4
#2C. Poettgen (University of Duisburg-Essen)H-Index: 5
Last. Martin Stuschke (University of Duisburg-Essen)H-Index: 55
view all 18 authors...
Purpose/Objective(s): The aim of this follow-up analysis of the ESPATUE phase-3 trial was to explore the prognostic value of post-induction chemotherapy PET metrics in patients with stage III non-small cell lung cancer (NSCLC) who were assigned to receive definitive chemoradiotherapy. Materials/Methods: All eligible patients stage IIIA (cN2) and stage IIIB of the trial received induction chemotherapy consisting of 3 cycles of cisplatin/paclitaxel and chemoradiotherapy up to 45 Gy/1.5 Gy per frac...